CPW
ESPR

Catalyst Private Wealth’s Esperion Therapeutics ESPR Stock Holding History

Catalyst Private Wealth’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-100
Closed -$4K – 126
2020
Q3 		$4K Buy
+100
New +$3.96K ﹤0.01% 245

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Catalyst Private Wealth's ESPR Position: Q4 2020 in Review

Catalyst Private Wealth sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 100 shares — an estimated $4K sold.

Catalyst Private Wealth first reported a position in ESPR in Q3 2020 and held it in 1 quarter. The position peaked at $4K in Q3 2020. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • Catalyst Private Wealth reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Catalyst Private Wealth sold 100 Esperion Therapeutics shares in Q4 2020, an estimated $4K.
  • Catalyst Private Wealth first reported a position in Esperion Therapeutics in Q3 2020 and held it in 1 quarter.
  • Catalyst Private Wealth's Esperion Therapeutics position peaked at $4K in Q3 2020.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Catalyst Private Wealth's 13F filing for Q4 2020, filed 5 Mar 2021.